LITE Study Proves Efficacy of Home Phototherapy

“Top line results of the study showed that treatment at home with phototherapy for plaque or guttate psoriasis is clearly noninferior to office-based treatments.” – Joel Gelfand M.D.

Introduction:

Preliminary results for the LITE Study, a three year long trial aimed at proving the efficacy of home phototherapy versus in-office treatments, have been revealed and the data is very promising for those seeking a safe and effective home treatment for plaque or guttate psoriasis.

Dr. Joel Gelfand, the leading physician of the study, stated the main reasoning for conducting the trial was in response to the conversations he and his colleagues would hear from their patients:

“…patients were motivated to learn more about home phototherapy. They feel like that’s a treatment they want better access to.”

The research was structured to seamlessly integrate into standard care practices. The eligibility criteria mirrored routine clinical procedures:

  1. Inclusion of patients aged 12 or older diagnosed with plaque and/or guttate psoriasis;
  2. Consent from participating clinicians who deemed the patient and their psoriasis suitable for either home or office phototherapy; and
  3. Willingness from the patient to be randomly assigned to either home or office phototherapy. Notably, there was no mandatory cessation of other psoriasis treatments except for phototherapy, which required discontinuation two weeks before randomization for those presently undergoing it.

Initial Findings:

The primary findings of the study underscored the evident noninferiority of home-based phototherapy for treating plaque or guttate psoriasis when compared to office-based treatments. Whether evaluating outcomes reported by physicians or patients, and regardless of skin type, it consistently demonstrated noninferiority across all metrics—a notably compelling discovery. Given the study’s nature, scale, and its practical and inclusive design, we believe this data warrants swift integration into clinical practice.

“Adding phototherapy to the mix can really help us maintain response, help people, and get to the ultimate objective we are trying to achieve for them. – Joel Gelfand M.D.

AAD 2024 Discussions:

Dr. Joel Gelfand will be presenting detailed information and data during a late breaking session at the 2024 American Academy of Dermatology Meeting in San Diego, California. 

Details are outlined below:

Date: Saturday, March 9  
Time: 9:50 am PST 
Room: 20BCD

 
Can’t make the breakout session? Come to the Daavlin booth to learn more.
 
Booth: #1339
 
 
 

To learn more about the LITE Study initial findings, click HERE

To learn more about the LITE Study, click HERE

To learn more about the phototherapy devices used during the LITE Study trial, click HERE